BioSpace News Archive

FDA response expected on or before June 30, 2020 Acasti also received notice of issuance of a Composition of Matter Patent in Hong Kong

XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the Company has filed its audited financial statements and related management’s discussion and analysis for the year ended December 31, 2019.

Healthcare expert joins executive team to advance clinical informatics throughout Affinitē™, the company’s end-to-end platform for predictive care coordination, quality improvement and risk adjustment

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2020 financial results on Thursday, May 7, 2020 , before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company’s website, www.aniphar

Latest FDA clearance establishes binx as the fastest dual-gender rapid test-and-treat platform for chlamydia and gonorrhea

AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41 st Annual Heart Rhythm Society (HRS) Virtual Meeting

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the appointment of biotech and finance industry veteran Ron Renaud as a director and non-executive chair of the board of directors. “We are honored to have Ron Renaud lead our board of directors

Rheonix Inc . Receives FDA Emergency Use Authorization for Rapid, Fully Automated Molecular COVID-19 Test

North American Partners in Anesthesia, one of the leading single-specialty anesthesia and perioperative management companies in the US, announces that it is expanding anesthesia services in Illinois with the addition of OSF Saint Anthony Medical Center in Rockford, Illinois.

Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2020. All figures are reported in U.S. dollars. Fiscal Year End 2020 Fiscal Year End 2019 Sales $5,141,341 $4,942,621 Net Income 250,886 230,946 Income per common share Basic 0.07 0.07 Diluted 0.07 0.07